Previous Pause Next
Home >> News Center >> Features >>
Collaboration, Projects & Consortia
Saab Extends Flight Hours Agreement with Scottish Loganair PDF Print E-mail
Friday, 07 October 2011 01:42

The Scottish airline Loganair has 16 Saab 340 aircraft and the new agreement encompasses component repairs and maintenance service within the PEP framework at the Aircraft Services division in the Support and Services business area.

KCI Announces Special Meeting of Shareholders to Vote on Merger Agreement with Consortium Led by Apax Partners PDF Print E-mail
Friday, 07 October 2011 01:33

Kinetic Concepts, Inc. (NYSE: KCI) today announced that on September 26, 2011, it filed with the Securities and Exchange Commission a definitive proxy statement in connection with the definitive merger agreement under which a consortium comprised of funds advised by Apax Partners, together with controlled affiliates of Canada Pension Plan Investment Board and the Public Sector Pension Investment Board, will acquire KCI for $68.50 per share in cash.

Dow & Argonne National Laboratory Collaborating on New Battery Materials PDF Print E-mail
Wednesday, 05 October 2011 06:48

The Dow Chemical Company (NYSE:DOW) and the U.S. Department of Energy's (DOE) Argonne National Laboratory today announced the signing of a Memorandum of Understanding (MOU) for a multi-year research collaboration to jointly develop the next generation of materials for advanced battery technologies.

DATATRAK Signs Multi-Year Agreement with Specialty Biotech PDF Print E-mail
Wednesday, 05 October 2011 06:46
DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the signing of a multi-year Enterprise Agreement with a specialty biologics and vaccines company.
MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from Pfizer PDF Print E-mail
Monday, 03 October 2011 18:45
MedImmune, the global biologics arm of AstraZeneca, today announced execution of an in-licensing agreement with Pfizer Inc for tremelimumab (CP-675,206), a CTLA-4 monoclonal antibody.
Verinata Enters Supply Agreement with Illumina for Sequencing Instruments PDF Print E-mail
Friday, 30 September 2011 21:00

Verinata Health is purchasing Illumina's sequencing platforms and consumables under a supply agreement. Terms of the deal allows Verinata to use the Illumina technology in the commercialization of its own noninvasive prenatal test, which is in development for detection of multiple fetal chromosome abnormalities.

SurgiCount Medical Announces Agreement with 130+ Hospital Operator to Implement the Safety-Sponge® System PDF Print E-mail
Wednesday, 28 September 2011 18:41
SurgiCount Medical, Inc., the wholly-owned operating subsidiary of Patient Safety Technologies, Inc. (OTCBB: PSTX, OTCQB: PSTX) today announced that it has signed an agreement, effective October 1st 2011, to implement the SurgiCount Safety-Sponge® System in one of the largest hospital operators in the U.S.  
Codexis, Raizen to Develop First Generation Ethanol PDF Print E-mail
Wednesday, 28 September 2011 18:39
Codexis, Inc. (Nasdaq: CDXS) and Raizen Energia S.A. today announced the signing of a joint development agreement to develop an improved first generation ethanol process with enhanced performance economics. Raizen is Brazil's largest sugar and ethanol producer.
Hypha Discovery Signs Natural Products Drug Discovery Collaboration With Ferrer Grupo PDF Print E-mail
Wednesday, 28 September 2011 01:51

Hypha Discovery Ltd (Hypha) today announced a collaboration with Ferrer Grupo to mine Hypha's MycoDiverse™ library to discover novel low molecular weight natural products to treat microbial infections.

The ETICS Project, Led by CYTOO in Collaboration With Cellectis bioresearch and the CEA, to Receive Euro 7.6 Million in Funding From OSEO PDF Print E-mail
Monday, 26 September 2011 16:48
CYTOO, a company that specializes in cell-based assays (Grenoble, France), has joined up with Cellectis bioresearch, the specialist in genome customization and commercial subsidiary of Cellectis (Alternext: ALCLS), and the CEA, the French Alternative Energies and Atomic Energy Commission, to develop new high-value cell-based assays for drug development and toxicology.
Unigene to Host Live Conference Call and Webcast to Discuss Collaboration with Nordic Bioscience and Formation of Joint Development Vehicle PDF Print E-mail
Friday, 07 October 2011 01:39

Unigene Laboratories, Inc. (OTCBB: UGNE) will host a live conference call and webcast today, October 6, 2011 at 11 a.m. Eastern Time to discuss the Company's announcement this morning regarding its decision to establish a Joint Development Vehicle (JDV) with Nordic Bioscience to progress up to three of Unigene’s internally developed, proprietary calcitonin analogs for the treatment of Type 2 diabetes, osteoarthritis and osteoporosis.

Gilead And Boehringer Ingelheim Sign License Agreement For Novel HIV Non-Catalytic Integrase Inhibitors PDF Print E-mail
Friday, 07 October 2011 00:59

Gilead Sciences, Inc. (Nasdaq:GILD) and Boehringer Ingelheim today announced that the companies have entered into a licensing agreement, under which Boehringer Ingelheim has granted Gilead exclusive worldwide rights for the research, development and commercialization of its novel non-catalytic site integrase inhibitors (NCINIs) for HIV.

Celgene and Agios Extend Cancer Metabolism Collaboration PDF Print E-mail
Wednesday, 05 October 2011 06:46

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, today announced that Celgene Corporation (NASDAQ: CELG) and Agios have agreed, ahead of schedule, to extend the initial period of exclusivity of the companies’ April 2010 collaboration agreement from three to four years.

ChemoMetec and De Novo Software to Co-market NucleoCounter® NC-3000™ and FCS Express 4 Image Cytometry Software PDF Print E-mail
Wednesday, 05 October 2011 06:44
De Novo Software™, a leading provider of flow and image cytometry data analysis solutions, and ChemoMetec, a provider of premiere bioresearch and pharmaceutical image cytometers, announced a co-marketing agreement today.
MedImmune Inks Deal for Pfizer's Anticancer mAb Therapeutic PDF Print E-mail
Monday, 03 October 2011 18:44

MedImmune inked an in-license agreement with Pfizer for tremelimumab, a mAb therapeutic for various types of cancer.

Sinclair IS Pharma and Invida Group Successfully Launch Leading Dermatology Brands Atopiclair and Papulex Across Seven Asia-Pacific Markets PDF Print E-mail
Friday, 30 September 2011 20:59

Sinclair IS Pharma Plc ("Sinclair IS" or “the Company”: SPH:L), the international specialty pharmaceutical company, and Invida Holdings Private Limited (“Invida”), a leader in the commercialisation of specialty biopharmaceutical and healthcare products throughout Asia Pacific, announce that their partnership has already led to the launch of two Sinclair IS dermatology products in seven Asia-Pacific markets.

Silence Therapeutics Signs siRNA Delivery Collaboration With Top 10 Pharma Company PDF Print E-mail
Wednesday, 28 September 2011 18:40

Silence Therapeutics plc (AIM: SLN) ("Silence"), a leading RNA interference (RNAi) therapeutics company, today announces that it has entered into an agreement with one of the world's leading global pharmaceutical companies to investigate the application of Silence's proprietary DACC delivery technology for intravenous delivery of short interfering RNA sequences ("siRNAs") to the pulmonary vascular endothelium.

CardioComm Solutions, Inc. and Monebo Technologies Sign Agreement to Develop Plug-and-Play GEMS ‘Triage’ Solution PDF Print E-mail
Wednesday, 28 September 2011 17:34

CardioComm Solutions, Inc. (TSX-V: EKG) announced today the recent signing of an agreement with Monebo Technologies, Inc. to develop a real-time ECG arrhythmia ‘triage’ solution.

Afraxis Joins NIH’s Therapeutics for Rare and Neglected Disease Program PDF Print E-mail
Monday, 26 September 2011 16:50

Afraxis will partner with the NIH under its Therapeutics for Rare and Neglected Disease (TRND) program to further development of its preclinical candidates for fragile X syndrome.

M4 Sciences Signs Agreement with Belgium-based NV Bekaert SA PDF Print E-mail
Monday, 26 September 2011 16:47

James Mann, CEO of M4 Sciences LLC, announced that M4 Sciences has signed a technology sub-license agreement for its Modulation-Assisted Machining (MAM)® technology.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 2 of 65